News & Updates

Tenofovir alafenamide (TAF) shows sustained safety and efficacy in heavily pretreated patients with multidrug-resistant hepatitis B virus (HBV) through 3 years of treatment, albeit leading to elevations in cholesterol levels.

The risk of hepatocellular carcinoma (HCC) among patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis is low, reveals a recent study. In addition, dose-dependent statin can substantially lower the risk of HCC in patients with NASH cirrhosis.

Burnout is experienced by nearly half (~40 percent) of hepatology providers during the COVID-19 pandemic, as shown by the negative impact of emotional well-being, including work fulfilment and satisfaction, according to a study.

New research suggests that COVID toe – a form of COVID-19–associated pernio or chilblains – may be a side effect of the immune system's response to fighting off the virus.

Peppermint oil appears to significantly improve symptoms of irritable bowel syndrome (IBS), as does placebo, with no significant differences between groups, reports a study.

In patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) who were receiving the novel nonsteroidal MRA* finerenone, use of SGLT-2is** at baseline did not influence treatment outcomes, according to a subgroup analysis of the FIDELITY*** trial presented at ASN 2021.

Switching from tenofovir disoproxil fumarate (TDF) regimens to tenofovir alafenamide (TAF) monotherapy demonstrates long-term efficacy and safety in orthotopic liver transplantation (OLT) recipients with chronic hepatitis B virus (HBV) infection, reports a study presented at The Liver Meeting Digital Experience 2021, by the American Association for the Study of Liver Diseases (AASLD 2021).